Collagenase Clostridium Histolyticum Injections Can Be an Effective Alternative to Surgical Intervention in Moderate to Severe Dupuytren’s Contracture by Biasca, Matthew R
Pacific University
CommonKnowledge
School of Physician Assistant Studies Theses, Dissertations and Capstone Projects
Spring 3-7-2016
Collagenase Clostridium Histolyticum Injections
Can Be an Effective Alternative to Surgical
Intervention in Moderate to Severe Dupuytren’s
Contracture
Matthew R. Biasca
Follow this and additional works at: http://commons.pacificu.edu/pa
Part of the Medicine and Health Sciences Commons
This Capstone Project is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at CommonKnowledge. It has
been accepted for inclusion in School of Physician Assistant Studies by an authorized administrator of CommonKnowledge. For more information,
please contact CommonKnowledge@pacificu.edu.
Recommended Citation
Biasca, Matthew R., "Collagenase Clostridium Histolyticum Injections Can Be an Effective Alternative to Surgical Intervention in
Moderate to Severe Dupuytren’s Contracture" (2016). School of Physician Assistant Studies. Paper 555.
Collagenase Clostridium Histolyticum Injections Can Be an Effective
Alternative to Surgical Intervention in Moderate to Severe Dupuytren’s
Contracture
Abstract
Background: Dupuytren’s contracture is a common debilitating fibroproliferative disease of the hand. The
current standard of care for moderate or severe Dupuytren’s is surgical fasciectomy. However, while surgery
yields a significant initial correction of the contracture, the recurrence rate is as high as 71% bringing into
question the efficacy of surgery and whether it is worth the surgical risk. Collagenase Clostridium
histolyticum (CCH) injections were approved by the FDA in February 2010 for the treatment of Dupuytren’s
contracture. This review evaluates the current literature that directly compares the efficacy of CCH injections
to surgical fasciectomies.
Methods: An exhaustive literature search using MEDLINE-Ovid, Web of Science, and CINAHL was
conducted. The following search terms were used: “Dupuytren’s contracture,” “collagenase,” and “fasciectomy.”
The search was further narrowed to include only English-language articles. Inclusion criteria consisted of
studies evaluating patients who initially present with a contracture of at least 30° and articles directly
evaluating the post interventional contracture degrees between CCH injections and fasciectomies. Studies
were excluded if their follow-up was less than 3 months and if multiple interventions were attempted during
the study. The studies were then evaluated for their quality using the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) Working Group Guidelines.
Results: Two studies were included in this systematic review, meeting both the inclusion and exclusion
criteria. One case-control retrospective study followed 142 patients with Dupuytren’s contracture and found
at latest follow-up that 46% of metacarpophalangeal (MCP) joints treated with CCH injections and 68% of
MCP joints treated with fasciectomy maintained joint contracture. Another propensity score matched study
evaluated 132 subjects and found that there was no significant residual contracture at MCP at latest followup
between fasciectomy and CCH injection groups. Fasciectomies did slightly better at the proximal
interphalangeal (PIP) joint compared to CCH injections.
Conclusion: CCH injections are a viable non-surgical option in the treatment of moderate to severe
Dupuytren’s contracture. Surgical fasciectomies are the current standard of care, but are subject to high
scrutiny due to the high level of recurrence that occurs post-procedurally, the relatively high risk of major
adverse events, and increased incidence of comorbidities found in the population with Dupuytren’s
contracture. It is difficult to discern how CCH injections compares to surgical fasciectomies, but early
research, such as the aforementioned discussed, suggest they are strong alternatives based on relative efficacy,
patient tolerance, and favorable safety profile. Further research will be needed to elucidate the clinical
importance of CCH injections in the treatment of Dupuytren’s contracture.
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|| Abstract || 
Background:  
Dupuytren’s contracture is a common debilitating fibroproliferative disease of the hand.  The current 
standard of care for moderate or severe Dupuytren’s is surgical fasciectomy.  However, while surgery 
yields a significant initial correction of the contracture, the recurrence rate is as high as 71% bringing into 
question the efficacy of surgery and whether it is worth the surgical risk. Collagenase Clostridium 
histolyticum (CCH) injections were approved by the FDA in February 2010 for the treatment of 
Dupuytren’s contracture. This review evaluates the current literature that directly compares the efficacy of 
CCH injections to surgical fasciectomies. 
Methods:   
An exhaustive literature search using MEDLINE-Ovid, Web of Science, and CINAHL was conducted. The 
following search terms were used: “Dupuytren’s contracture,” “collagenase,” and “fasciectomy.”  The 
search was further narrowed to include only English-language articles.  Inclusion criteria consisted of 
studies evaluating patients who initially present with a contracture of at least 30° and articles directly 
evaluating the post interventional contracture degrees between CCH injections and fasciectomies. Studies 
were excluded if their follow-up was less than 3 months and if multiple interventions were attempted 
during the study.   The studies were then evaluated for their quality using the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) Working Group Guidelines. 
Results:  
Two studies were included in this systematic review, meeting both the inclusion and exclusion criteria.  
One case-control retrospective study followed 142 patients with Dupuytren’s contracture and found at latest 
follow-up that 46% of metacarpophalangeal (MCP) joints treated with CCH injections and 68% of MCP 
joints treated with fasciectomy maintained joint contracture.  Another propensity score matched study 
evaluated 132 subjects and found that there was no significant residual contracture at MCP at latest follow-
up between fasciectomy and CCH injection groups.  Fasciectomies did slightly better at the proximal 
interphalangeal (PIP) joint compared to CCH injections.   
Conclusion:  
CCH injections are a viable non-surgical option in the treatment of moderate to severe Dupuytren’s 
contracture.  Surgical fasciectomies are the current standard of care, but are subject to high scrutiny due to 
the high level of recurrence that occurs post-procedurally, the relatively high risk of major adverse events, 
and increased incidence of comorbidities found in the population with Dupuytren’s contracture.  It is 
difficult to discern how CCH injections compares to surgical fasciectomies, but early research, such as the 
aforementioned discussed, suggest they are strong alternatives based on relative efficacy, patient tolerance, 
and favorable safety profile.  Further research will be needed to elucidate the clinical importance of CCH 
injections in the treatment of Dupuytren’s contracture. 
Keywords:  
Dupuytren’s contracture, collagenase, fasciectomy 
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Collagenase Clostridium Histolyticum Injections Can Be an Effective 
Alternative to Surgical Intervention in Moderate to Severe Dupuytren’s 
Contracture 
BACKGROUND 
Dupuytren’s contracture is a common and disabling fibroproliferative condition of 
the hand. 1 This disease most often occurs in elderly males, with a mean diagnosed age of 
55 years, and has a high prevalence in those with Northern European descent.   Two 
million people are believed to have the condition in the United Kingdom alone. 2  
Pathologically, Dupuytren’s contracture results in fibroblastic proliferation and 
uninhibited type III collagen deposition. 2 The etiology of Dupuytren’s disease, however, 
is largely unknown.  There is strong research that suggests an autosomal dominant trait 
with incomplete inheritance involving genes encoding a Wnt signaling pathway, which 
promotes cellular proliferation. 3  Other research finds a strong correlation between those 
with diabetes, smoking, and heavy alcohol intake. 4 
Deformities of the normal anatomy determine where the greatest contractures will 
occur.  The skin pitting, normally seen earlier in the disease progression, is the result of 
involvement of the small vertical fibers.  Abnormal development of the pretendinous 
band will result in metacarpophalangeal joint (MCP) contracture.  Involvement of the 
lateral digital sheet causes flexion at the proximal interphalangeal (PIP) joint, while 
irregularity at the spiral cord results in both PIP and MCP contracture. 2 
Those who seek medical attention for Dupuytren’s contracture often complain of 
difficulty with daily activities such as shaking hands, combing their hair, or catching their 
hand on their pocket. 5 The current standard of care for moderate to severe Dupuytren’s 
contracture is surgical fasciectomy. 6 While surgery yields a significant initial correction 
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of contracture and improved functionality, recurrence rates have been reported to be as 
high as 71%. 7 Additionally, patients with Dupuytren’s contracture often have existing 
comorbidities (eg, advanced age, smokers, diabetes) that complicate surgery and/or make 
surgery a suboptimal option. 8 Approximately 15% of cases of fasciectomies have 
associated major complications including: digital nerve injury (3.4%), digital artery 
injury (2%), infection (2.4%), and complex regional pain syndrome (5.5%). 9 
Collagenase Clostridium histolyticum (CCH) injections are a new, nonsurgical 
alternative to the treatment of Dupuytren’s contracture.  CCH consist of 2 collagenase 
proteins produced and isolated from Clostridium histolyticum that cleave the triple helical 
structure of collagen molecules 10,11.  CCH injections were approved by the FDA in the 
United States for the treatment of Dupuytren’s contracture in February 2010 after 
multiple prospective, multicenter clinical trials demonstrated its short-term efficacy 
compared to placebo 12,13.  When comparing the efficacy of CCH injections to the current 
standard of care (surgical fasciectomies), can CCH injections truly are a viable non-
surgical option for the treatment of Dupuytren’s contracture? 
METHODS 
An exhaustive literature search using MEDLINE-Ovid, Web of Science, and 
CINAHL was conducted. The following search terms were used: “Dupuytren’s 
contracture,” “collagenase” and “fasciectomy.”  The search was further narrowed to 
include only English-language articles.  Inclusion criteria consisted of patient’s initially 
presenting with a contracture of at least 30°, articles directly comparing the post 
interventional contracture degrees between CCH injections and fasciectomies. Studies 
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were excluded if their follow-up was less than 3 months and if multiple interventions 
were attempted during the study.   The studies were then evaluated for their quality using 
the Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
Working Group Guidelines 14. 
RESULTS 
The search generated 27 articles.  Applying the aforementioned inclusion and 
exclusion criteria resulted in 2 articles.  The first article 15, a case-control retrospective 
study reviewed the electronic records at a single academic hand surgical center from 
January 2009 through January 2013.  The second 16, a propensity score-matched study 
found patients from one of seven practices in the Netherlands from August 2011 to 
March 2014 through a prospectively maintained database. See Table 1. 
Muppavarapu et al 
This case-control retrospective study 15 aimed to compare the efficacy of 
collagenase injections with fasciectomy in the treatment of Dupuytren’s contracture 15.  
The electronic medical records were reviewed at a single academic hand surgical center 
from January 2009 through January 2013 by 3 surgeons who had previously participated 
in the CORD-2 trial and utilized a standardized data collection form.  Primary outcome 
measurements was the resolution of joint contracture of 0-5° deficit of full extension. 
Secondary outcomes included measurements of the magnitude of residual flexion 
contracture and adverse events following each intervention.  Statistical analysis was 
performed with the R statistical programming language using two sample t tests 
continuous data and chi-square test for categorical data 15. 
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A total of 142 patients were identified from the medical records, 81 underwent 
CCH injections while 61 underwent fasciectomies.  Fourteen were excluded due to 
having secondary procedures performed. 1-year follow up data was available for 117 of 
the remaining 128 patients: 44 patients (94 joints) underwent fasciectomies and 73 
patients (100 joints) underwent CCH injections.  In the collagenase group, 51 out of the 
100 joints met the primary endpoint at early follow-up.  Additionally, 25 of those 51 
(49%) joints continued to meet the primary endpoint goal at latest follow-up.  In the 
fasciectomy group, 66 of the 94 (70%) joints met the primary endpoint at early follow-up.  
56 of those 94 (60%) joints continued to meet the primary endpoint goal at latest follow-
up. Individual analysis found that MCP joints responded more positively compared to 
PIP joints with both CCH injections and fasciectomies.  Analysis of secondary outcomes 
found the mean residual joint contracture was less in the fasciectomy group compared to 
the CCH injection group at latest follow up (28.4° vs. 11.8°) 15.  
The article also discussed adverse events between the two groups.  Over 70% of 
the patients in the CCH injection group reported mild adverse effects including local 
edema, ecchymosis, and pain.  Skin tearing occurred in 18% of patients following manual 
manipulation.  No infections were reported.  The fasciectomy group reported 1 case of 
digital neurovascular injury (2.2%), which required microsurgical primary repair.  Two 
cases of deep wound infection were also reported; both of which resulted in subsequent 
irrigation, debridement, and oral antibiotics 15. 
The authors concluded that fasciectomies were more likely to have better 
correction of Dupuytren’s contracture at 1-year follow up. They also determined that both 
interventions had poorer results at the PIP joint compared to the MCP joint.  They 
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theorized that surgical fasciectomy allowed for more complete excision of the cord tissue 
and resulted in slower contracture recurrence.  The authors further went on to say that 
CCH injections remained a viable, non-operative treatment due to the fact that they were 
generally well tolerated by patients, had a more favorable safety profile, and allowed 
patients to return to work/activity sooner 15. 
Zhou et al 
The purpose of this study 16 was to directly compare the early clinical results of 
CCH injections and limited fasciectomies with the use of propensity scoring in order to 
avoid confounding variables.  Patients were gathered from August 2011 to March 2014 
amongst 7 practice sites in the Netherlands using a prospectively maintained database 16.   
 CCH injections were administered according to the manufacturer’s instruction 
and dosage was limited to 0.20 mL and 0.25 mL.  Treated fingers were manually 
manipulated 24-72 hours after the administered injection.  Limited fasciectomy was 
performed with tourniquet exsanguination and loupe magnification.  Cords were 
approved by Bruner type incisions with Z-plasties 16.  
 Originally, 397 patients were found for this study, which resulted in 218 being 
eligible after exclusion criteria. From this group, 66 CCH injection patients and 66 
limited fasciectomy patients were considered matched through propensity scores 16.  
 At the MCP joint, no significant difference was found between the CCH injection 
group and limited fasciectomy groups residual contracture  (13° vs. 6°, p=0.095).  At the 
PIP joint, the degree of residual contracture was slightly better with limited fasciectomy 
(25° vs. 15°, p= 0.010).  Again this study found that both interventions performed better 
at the MCP vs. PIP 16. 
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 This study also included the Michigan Hand Outcomes Questionnaire as a 
measure for patient satisfaction as a secondary outcome.  CCH was found to have 
significantly larger improvements than limited fasciectomies in overall satisfaction, 
activities of daily living, and work performance; fasciectomies only performing better in 
overall hand appearance 16. 
 All major adverse events were found to be in the fasciectomy group. Three events 
of tenosynovitis were reported and required further intervention as well as one example 
of nerve injury.  The CCH injection group reported high levels of local mild adverse 
events: peripheral edema (74%), contusion (64%) and extremity pain (26%) 16. 
 The authors concluded that CCH injections were a viable option compared to 
limited fasciectomy at both the PIP and MCP joint.  The authors had stated that patients 
who were willing to sacrifice maximal contracture correction for quicker recovery rate 
and avoidance of surgery would likely be happier with a CCH injection.  They continued 
to state that their research is limited due to the length of follow-up and more long-term 
follow-up for recurrence would be need to better understand the efficacy of CCH 
injections 16. 
DISCUSSION 
 Both studies 15,16 found that CCH injection recipients were found to have more 
residual contracture on follow-up compared to surgical fasciectomy, however, Zhou et al 
15,16 found a more prominent statistically significant difference in contracture compared 
to the Muppavarapu et al. study 15,16.  Additionally, both found that fasciectomies and 
CCH injections both performed worse at residual contracture at the PIP joint as compared 
to the MCP joint.  The authors surmised that the recurrence following the CCH injections 
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was overall understanding because it simply disrupts the collagen cord and does not 
address the disease process itself, as opposed to open fasciectomy, in which more 
complete and precise excision is possible. Despite CCH injections performing worse in 
residual contracture compared to surgical fasciectomy, both studies 15,16 concluded that 
CCH injections were a viable non-surgical option in moderate to severe Dupuytren’s 
Contracture.  While patients in the CCH injection groups experience more frequent local 
reactions, it was overall tolerated well and had a favorable safety profile.  Zhou et al 16 
speculated that the CCH injection group scored better in multiple categories in their 
Michigan Hand Outcomes Questionnaire, which indicated that hand function returned 
quicker with CCH injections compared to surgical fasciectomy.   
Further research in CCH injections suggests its viability in the clinical setting.  
Early long-term evaluation of recurrence by the CORDLESS study finds that CCH 
injections show similar recurrence rates to surgical fasciectomy at 3-year 17 and 5-year 18 
follow-ups.  Both of these studies 17,18 utilized the manufacture’s guidelines on how to 
administer the CCH injections, namely one injection per cord at each encounter, but 
newer research indicates 19,20 that there is little risk involved for the patient with multiple 
injections and would require further investigation to determine if CCH injection efficacy 
is affected.  Lastly, research in the United Kingdom showed that the current 
administration of CCH injections could be as high as 3 times more cost effective than 
surgical fasciectomy 21.  
Several limitations were identified in these studies during appraisal.  Both were 
retrospective case control studies and inherently have limitations as compared to 
randomized controlled trials.  Secondly, each study had a limited population size: n=132 
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in Zhou et al study 16 and n=194 in the Muppavarapu et al. study 15.  The length of follow-
up was too short in the context of discussing Dupuytren’s contracture considering that the 
current standard of care, surgical fasciectomy, has a potential recurrence rate as high as 
71% 7.  Zhou et al 16 addresses this concern and state their deliberate intent to address 
early clinical outcomes because so few studies have compared CCH injections to surgical 
fasciectomies in their initial efficacy and associated risks.  Additionally, this article’s 
findings could be confounded due to patients with both primary and recurrent disease in 
their population.  Finally, several authors disclosed that they had been prior consultants to 
Pzier and Sobi, two European manufactures of injectable collagenase, which inherently 
brings to question the quality of their research.  The article states that support was 
received from Pfizer only in the form of injections that were provided for free.  The 
Muppavarapu et al 15study had no standardized protocol for post intervention care 
including, hand splinting and hand therapy, creating an unknown variable in the results 
presented. 
 While these studies are both retrospective studies with inherent limitations and a 
small population size, they indicate that CCH injections may potentially be a viable tool 
in the treatment of Dupuytren’s contracture.  Further randomized controlled trials with 
blinded clinical evaluators would be needed to further clarify the true efficacy of CCH 
injections compared to surgical fasciectomy. 
   
CONCLUSION  
 CCH injections are a viable non-surgical option in the treatment of moderate to 
severe Dupuytren’s contracture.  Surgical fasciectomies are the current standard of care, 
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but are subject to high scrutiny due to the high level of recurrence that occurs post-
procedurally, the relatively high risk of major adverse events, and increased incidence of 
comorbidities found the population with Dupuytren’s contracture 6-8.  It is difficult to 
discern how CCH injections compares to surgical fasciectomies, but early research, such 
as the aforementioned discussed, suggest they are strong alternatives based on relative 
efficacy, patient tolerance, and favorable safety profile. Further research will be needed to 
elucidate the clinical importance of CCH injections in the treatment of Dupuytren’s 
contracture. 
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Table 1: Quality Assessment of Reviewed Articles 
Study Design 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Muppavarapu 
et al 
Case 
Control 
Seriousa Not Serious Not Serious Seriousb Not Likely None 
Very 
low 
Zhou et el 
Propensity 
score 
matched 
study 
Not 
Serious 
Not Serious Not Serious Seriousb Likelyc None 
 Very 
Low 
aDid not account for post procedural splinting and hand therapy 
bSmall sample size 
cPrevious authors have consulted with manufacturing companies previously 
 
 
 
